Linked Life Data

18060403

Source:http://linkedlifedata.com/resource/pubmed/id/18060403

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2008-7-21
pubmed:abstractText
Immune escape by tumors can occur by multiple mechanisms, each a significant barrier to immunotherapy. We previously demonstrated that upregulation of the immunosuppressive molecule CD200 on chronic lymphocytic leukemia cells inhibits Th1 cytokine production required for an effective cytotoxic T cell response. CD200 expression on human tumor cells in animal models prevents human lymphocytes from rejecting the tumor; treatment with an antagonistic anti-CD200 antibody restored lymphocyte-mediated tumor growth inhibition. The current study evaluated CD200 expression on solid cancers, and its effect on immune response in vitro.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0340-7004
pubmed:author
pubmed:issnType
Print
pubmed:volume
57
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
987-96
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200.
pubmed:affiliation
Alexion Antibody Technologies, Inc., 3985 Sorrento Valley Blvd, Ste A, San Diego, CA 92121, USA.
pubmed:publicationType
Journal Article